David W Hein1, Mark A Doll. 1. Department of Pharmacology & Toxicology, University of Louisville Health Sciences Center, Louisville, KY 40202-1617, USA.
Abstract
AIM: Humans exhibit genetic polymorphism in NAT2 resulting in rapid, intermediate and slow acetylator phenotypes. Over 65 NAT2 variants possessing one or more SNPs in the 870-bp NAT2 coding region have been reported. The seven most frequent SNPs are rs1801279 (191G>A), rs1041983 (282C>T), rs1801280 (341T>C), rs1799929 (481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 (857G>A). The majority of studies investigate the NAT2 genotype assay for three SNPs: 481C>T, 590G>A and 857G>A. A tag-SNP (rs1495741) recently identified in a genome-wide association study has also been proposed as a biomarker for the NAT2 phenotype. MATERIALS & METHODS: Sulfamethazine N-acetyltransferase catalytic activities were measured in cryopreserved human hepatocytes from a convenience sample of individuals in the USA with an ethnic frequency similar to the 2010 US population census. These activities were segregated by the tag-SNP rs1495741 and each of the seven SNPs described above. We assessed the accuracy of the tag-SNP and various two-, three-, four- and seven-SNP genotyping panels for their ability to accurately infer NAT2 phenotype. RESULTS: The accuracy of the various NAT2 SNP genotype panels to infer NAT2 phenotype were as follows: seven-SNP: 98.4%; tag-SNP: 77.7%; two-SNP: 96.1%; three-SNP: 92.2%; and four-SNP: 98.4%. CONCLUSION: A NAT2 four-SNP genotype panel of rs1801279 (191G>A), rs1801280 (341T>C), rs1799930 (590G>A) and rs1799931 (857G>A) infers NAT2 acetylator phenotype with high accuracy, and is recommended over the tag-, two-, three- and (for economy of scale) the seven-SNP genotyping panels, particularly in populations of non-European ancestry.
AIM: Humans exhibit genetic polymorphism in NAT2 resulting in rapid, intermediate and slow acetylator phenotypes. Over 65 NAT2 variants possessing one or more SNPs in the 870-bp NAT2 coding region have been reported. The seven most frequent SNPs are rs1801279 (191G>A), rs1041983 (282C>T), rs1801280 (341T>C), rs1799929 (481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 (857G>A). The majority of studies investigate the NAT2 genotype assay for three SNPs: 481C>T, 590G>A and 857G>A. A tag-SNP (rs1495741) recently identified in a genome-wide association study has also been proposed as a biomarker for the NAT2 phenotype. MATERIALS & METHODS:Sulfamethazine N-acetyltransferase catalytic activities were measured in cryopreserved human hepatocytes from a convenience sample of individuals in the USA with an ethnic frequency similar to the 2010 US population census. These activities were segregated by the tag-SNP rs1495741 and each of the seven SNPs described above. We assessed the accuracy of the tag-SNP and various two-, three-, four- and seven-SNP genotyping panels for their ability to accurately infer NAT2 phenotype. RESULTS: The accuracy of the various NAT2 SNP genotype panels to infer NAT2 phenotype were as follows: seven-SNP: 98.4%; tag-SNP: 77.7%; two-SNP: 96.1%; three-SNP: 92.2%; and four-SNP: 98.4%. CONCLUSION: A NAT2 four-SNP genotype panel of rs1801279 (191G>A), rs1801280 (341T>C), rs1799930 (590G>A) and rs1799931 (857G>A) infers NAT2 acetylator phenotype with high accuracy, and is recommended over the tag-, two-, three- and (for economy of scale) the seven-SNP genotyping panels, particularly in populations of non-European ancestry.
Authors: D M Grant; N C Hughes; S A Janezic; G H Goodfellow; H J Chen; A Gaedigk; V L Yu; R Grewal Journal: Mutat Res Date: 1997-05-12 Impact factor: 2.433
Authors: Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan Journal: BMC Med Genet Date: 2012-03-17 Impact factor: 2.103
Authors: Olayinka A Kotila; Olufunmilayo I Fawole; Olufunmilayo I Olopade; Adejumoke I Ayede; Adeyinka G Falusi; Chinedum P Babalola Journal: Pharmacogenet Genomics Date: 2019-07 Impact factor: 2.089
Authors: Todd M Gibson; Karin E Smedby; Christine F Skibola; David W Hein; Susan L Slager; Silvia de Sanjosé; Claire M Vajdic; Yawei Zhang; Brian C-H Chiu; Sophia S Wang; Henrik Hjalgrim; Alexandra Nieters; Paige M Bracci; Anne Kricker; Tongzhang Zheng; Carol Kolar; James R Cerhan; Hatef Darabi; Nikolaus Becker; Lucia Conde; Theodore R Holford; Dennis D Weisenburger; Anneclaire J De Roos; Katja Butterbach; Jacques Riby; Wendy Cozen; Yolanda Benavente; Casey Palmers; Elizabeth A Holly; Joshua N Sampson; Nathaniel Rothman; Bruce K Armstrong; Lindsay M Morton Journal: Cancer Causes Control Date: 2012-11-18 Impact factor: 2.506
Authors: L V Kalman; Jag Agúndez; M Lindqvist Appell; J L Black; G C Bell; S Boukouvala; C Bruckner; E Bruford; K Caudle; S A Coulthard; A K Daly; Al Del Tredici; J T den Dunnen; K Drozda; R E Everts; D Flockhart; R R Freimuth; A Gaedigk; H Hachad; T Hartshorne; M Ingelman-Sundberg; T E Klein; V M Lauschke; D R Maglott; H L McLeod; G A McMillin; U A Meyer; D J Müller; D A Nickerson; W S Oetting; M Pacanowski; V M Pratt; M V Relling; A Roberts; W S Rubinstein; K Sangkuhl; M Schwab; S A Scott; S C Sim; R K Thirumaran; L H Toji; R F Tyndale; Rhn van Schaik; M Whirl-Carrillo; Ktj Yeo; U M Zanger Journal: Clin Pharmacol Ther Date: 2015-11-20 Impact factor: 6.875